tirzepatide no longer shortage GLP-1 on FDA's Drug List FDA Announces End of Tirzepatide

Yes, if tirzepatide remains ineffective after optimization of dose, adherence, and lifestyle factors, switching to alternative GLP-1 receptor agonists like semaglutide or adding complementary diabetes medications may be appropriate

Depression often develops after major life stressors such as loss, trauma, or chronic illness, but it can also appear without a clear cause

SURMOUNT-1 showed substantial average weight reductions across doses, with the largest at 15 mg, alongside lifestyle support

Comprehensive Health Benefits: Promotes enhanced physical mobility and assists in lowering key cardiovascular risk factors

Mody R, Yu M, Nepal B, Konig M, Grabner M

Perrott J, et al